BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 21377293)

  • 1. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
    Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
    Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.
    Zhang X; Liu H; Balter P; Allen PK; Komaki R; Pan T; Chuang HH; Chang JY
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1558-65. PubMed ID: 22572078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer.
    Temming S; Kocher M; Stoelben E; Hagmeyer L; Chang DH; Frank K; Hekmat K; Wolf J; Baus WW; Semrau R; Baues C; Marnitz S
    Strahlenther Onkol; 2018 Feb; 194(2):91-97. PubMed ID: 28812120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
    Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
    Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
    Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
    Tanaka H; Hayashi S; Hoshi H
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
    Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
    J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
    Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
    Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).
    Videtic GM; Hu C; Singh AK; Chang JY; Parker W; Olivier KR; Schild SE; Komaki R; Urbanic JJ; Timmerman RD; Choy H
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):757-64. PubMed ID: 26530743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.
    Fakiris AJ; McGarry RC; Yiannoutsos CT; Papiez L; Williams M; Henderson MA; Timmerman R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):677-82. PubMed ID: 19251380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?
    Clarke K; Taremi M; Dahele M; Freeman M; Fung S; Franks K; Bezjak A; Brade A; Cho J; Hope A; Sun A
    Radiother Oncol; 2012 Jul; 104(1):62-6. PubMed ID: 22682749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer.
    Videtic GM; Stephans KL; Woody NM; Reddy CA; Zhuang T; Magnelli A; Djemil T
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):203-8. PubMed ID: 25015198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.
    Schanne DH; Nestle U; Allgäuer M; Andratschke N; Appold S; Dieckmann U; Ernst I; Ganswindt U; Grosu AL; Holy R; Molls M; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Guckenberger M
    Strahlenther Onkol; 2015 Feb; 191(2):125-32. PubMed ID: 25159135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.
    Grills IS; Hope AJ; Guckenberger M; Kestin LL; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Belderbos J
    J Thorac Oncol; 2012 Sep; 7(9):1382-93. PubMed ID: 22843086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.